This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering

Emerging technologies in antibody engineering and therapeutics

Monoclonal antibodies are expected to make up just under half of the USD $22.7 billion biologics discovery market by 2025. With this comes great technological innovation and novel approaches to antibody engineering and therapeutics. This whitepaper discusses the latest strategies and challenges, looking at:

- Automation
- Immune repertoire analysis
- Next Generation Sequencing and Bioinformatics
- Display technology and antibody characteristics
- Bispecific Antibodies
- The Challenges of mAbs
- Next generations “antibody-like” protein therapeutics

To download the exclusive whitepaper simply log in or register for an Informa Connect account, which will give you access to all our exclusive premium content.

Have any questions about the whitepaper or interested in sponsoring a future whitepaper? Email

This piece represents the views of the author and not necessarily the views of Informa Connect Life Sciences or the Antibody Therapeutics and Engineering conference series.

Log in or Create an Informa Connect Account to Access this content

Creating an account also means you'll get special access to article updates and exclusive industry content.